Niki Arya

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs

Mikhail Kosiborod, Matthew A. Cavender, Alex Z. Fu et al. · Circulation · 2017 · 791 citations · Full text

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

Paolo A. Ascierto, David R. Minor, Antoni Ribas et al. · Journal of Clinical Oncology · 2013 · 422 citations

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

Chantal Mathieu, Paresh Dandona, Pieter Gillard et al. · Diabetes Care · 2018 · 245 citations

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial

Rosalie A. Scholtes, Marcel H.A. Muskiet, Michiel J.B. van Baar et al. · Diabetes Care · 2020 · 116 citations · Full text

Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects

Ivy Song, Julie Borland, Niki Arya et al. · The Journal of Clinical Pharmacology · 2014 · 101 citations · Full text

Nutrition, Nutrient Bioavailability, Dolutegravir Exposure +13